Back to results
US 2024/0199727 A1Published application
Anti-ngf antibodies and uses thereof
AssigneeInvetx, Inc.
InventorsWilliam BRONDYK, Jordan WILLIS, Leila SEVIGNY
Life of this patent
Estimating the term…
Abstract
The invention provides novel anti-NGF proteins, antibodies, and NGF-binding fragments thereof which inhibit association of NGF with TrkA and/or p75 and are suitable for administration to a canine or feline subject. The invention also provides novel compositions and methods of treating pain or eliciting an analgesic effect in a canine or feline subject, comprising administering an effective amount of an anti-NGF protein, antibody or fragment thereof. The methods and compositions are used to treat or prevent NGF-related disorders.
Claims23
An antigen binding protein that specifically binds to NGF, which comprises:
- (a) a heavy chain complementarity determining region 1 (VH-CDR1) comprising the amino acid sequence X1LX3X4X5X6X7X8MX10, wherein X1 comprises A, G, L, N, or Q, X3 comprises A, D, E, G, H, I, M, S, T, or Y, X4 comprises L, M, or V, X5 comprises A, M, N, R, S, T, or V, X6 comprises A, E, G, H, K, R, S, or T, X7 comprises A, D, H, I, N, Q, S, T, or Y, X8 comprises A or S, and X10 comprises S or V;
- (b) a heavy chain complementarity determining region 2 (VH-CDR2) comprising the amino acid sequence X1X2X3X4X5GTX8YX10DX12VX14, wherein X1 comprises I or L, X2 comprises W or Y;
- X3 comprises A, P, or S, X4 comprises D, E, N, Q, R, or S, X5 comprises G, R, or Y, X8 comprises D or Y, X10 comprises D, E, H, S, or T, X12 comprises D or S, and X14 comprises D, E, or K;
- (c) a heavy chain complementarity determining region 3 (VH-CDR3) comprising the amino acid sequence X1X2X3X4X5X6X7X8X9X10LX12X13X14FX16X17, wherein X1 comprises A, D, E, K, N, Q, S, or T, X2 comprises A, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or Y, X3 comprises I, L, W, or Y, X4 comprises F, T, W, or Y, X5 comprises F, H, or Y, X6 comprises H or Y, X7 comprises D or E, X8 comprises A, S, or V, X9 comprises D, E, H, K, N, Q, or Y, X10 comprises F, H, or Y, X12 comprises H or Y, X13 comprises F or W, X14 comprises D, I, L, W, or Y, X 16 comprises D or Q, and X17 comprises E, F, H, I, L, M, N, P, W, or Y;
- (d) a light chain complementarity determining region 1 (VL-CDR1) comprising the amino acid sequence X1ASX4X5X6X7X8X9LX11, wherein X1 comprises F or R, X4 comprises E, K, or N, X5 comprises A, or G, X6 comprises I, L, or V, X7 comprises A, D, G, L, P, Q, S, V, or Y, X8 comprises K, Q, N, S, or Y, X9 comprises A, D, E, F, G, H, K, L, N, Q, R, S or T, and X11 comprises A, G, or S;
- (e) a light chain complementarity determining region 2 (VL-CDR2) comprising the amino acid sequence AX2X3X4X5X6X7, wherein X2 comprises A, D, L, Q, S, T, V, or Y, X3 comprises D, E, K, N, Q, or S, X4 comprises H, I, K, L, M, N, or V;
- X5 comprises H or L, X6 comprises H, I, L, or M, and X7 comprises D, E, N, S, or T;
- (f) a light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence QQX3X4X5X6X7X8T, wherein X3 comprises G or Y, X4 comprises D, F, G, H, K, L, R, S, T, V, W, or Y, X5 comprises E, K, Q, R, or S, X6 comprises I, F, T, or W, X7 comprises E or P, and X8 comprises L, M, or W.
5 more elements
Dependencies are inferred from the claim text.